The aim of the study was to examine the potential of perftoran for the treatment of patients with critical lower limb ischemia, in whom surgical revascularization appeared not feasible in view of the type of lesion or severity of concomitant pathology. The study accrued 85 patients distributed into the basic and control groups. The control group patients (n=40) received the basic conservative therapy including rheological, vasoactive drugs, anticoagulants and aggregation inhibitors. Patients entering the basic group (n=45) were administered perftoran infusions together with the basic therapy protocol. We examined the time course of changes in the painful syndrome, ascertained the degree of ischemia, the extent of trophic disorders, the parameters of the peripheral flow in the pedal arteries by ultrasound Doppler (USD), and the intensity of the manifestations of the systemic inflammatory response. It has been proven that the use of perftoran is justified and that the preparation may be recommended for use in multimodality treatment of the patient group under consideration.